These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21954046)

  • 21. Combined MRI and MRS in prostate cancer: improvement of spectral quality by susceptibility matching.
    Scheidler J; Vogel M; Gross P; Heuck A
    Rofo; 2009 Jun; 181(6):531-5. PubMed ID: 19353482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Quality 3-Dimensional 1H Magnetic Resonance Spectroscopic Imaging of the Prostate Without Endorectal Receive Coil Using A Semi-LASER Sequence.
    Tayari N; Steinseifer IK; Selnæs KM; Bathen TF; Maas MC; Heerschap A
    Invest Radiol; 2017 Oct; 52(10):640-646. PubMed ID: 28632688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Value of 3D 1H-MRS with body coil at 3T in the differential diagnosis of the prostate cancer].
    Wang F; Dai YP; Sun XZ; Guo Y; Chen YQ; Mao LJ; Wang DH; Deng CH
    Zhonghua Nan Ke Xue; 2009 May; 15(5):431-6. PubMed ID: 19514556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.
    Kline EE; Treat EG; Averna TA; Davis MS; Smith AY; Sillerud LO
    J Urol; 2006 Nov; 176(5):2274-9. PubMed ID: 17070311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
    Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
    Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study.
    Scheenen TW; Fütterer J; Weiland E; van Hecke P; Lemort M; Zechmann C; Schlemmer HP; Broome D; Villeirs G; Lu J; Barentsz J; Roell S; Heerschap A
    Invest Radiol; 2011 Jan; 46(1):25-33. PubMed ID: 21188832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (31) P MR spectroscopic imaging combined with (1) H MR spectroscopic imaging in the human prostate using a double tuned endorectal coil at 7T.
    Luttje MP; Italiaander MG; Arteaga de Castro CS; van der Kemp WJ; Luijten PR; van Vulpen M; van der Heide UA; Klomp DW
    Magn Reson Med; 2014 Dec; 72(6):1516-21. PubMed ID: 24357271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions.
    Hom JJ; Coakley FV; Simko JP; Qayyum A; Lu Y; Schmitt L; Carroll PR; Kurhanewicz J
    Radiology; 2006 Jan; 238(1):192-9. PubMed ID: 16373767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI spectroscopy in screening of prostate cancer.
    Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
    Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.
    Crehange G; Maingon P; Gauthier M; Parfait S; Cochet A; Mirjolet C; Bonnetain F; Cormier L; Brunotte F; Walker P
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e407-13. PubMed ID: 21605949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy.
    Dhingsa R; Qayyum A; Coakley FV; Lu Y; Jones KD; Swanson MG; Carroll PR; Hricak H; Kurhanewicz J
    Radiology; 2004 Jan; 230(1):215-20. PubMed ID: 14695396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate.
    Fütterer JJ; Scheenen TW; Heijmink SW; Huisman HJ; Hulsbergen-Van de Kaa CA; Witjes JA; Heerschap A; Barentsz JO
    Invest Radiol; 2007 Feb; 42(2):116-22. PubMed ID: 17220729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
    Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D ¹H MR spectroscopic imaging: correlation with pathologic findings.
    Giusti S; Caramella D; Fruzzetti E; Lazzereschi M; Tognetti A; Bartolozzi C
    Abdom Imaging; 2010 Dec; 35(6):757-63. PubMed ID: 19756851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal B0 field variation effects on MRSI of the human prostate at 7 T and feasibility of correction using an internal field probe.
    Arteaga de Castro CS; Boer VO; Luttje MP; van der Velden TA; Bhogal A; van Vulpen M; Luijten PR; van der Heide UA; Klomp DW
    NMR Biomed; 2014 Nov; 27(11):1353-60. PubMed ID: 25212868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.
    Heerschap A; Jager GJ; van der Graaf M; Barentsz JO; de la Rosette JJ; Oosterhof GO; Ruijter ET; Ruijs SH
    Anticancer Res; 1997; 17(3A):1455-60. PubMed ID: 9179183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton MR spectroscopy of the prostate.
    Mueller-Lisse UG; Scherr MK
    Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue.
    Hosseinzadeh K; Schwarz SD
    J Magn Reson Imaging; 2004 Oct; 20(4):654-61. PubMed ID: 15390142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.